非霍奇金淋巴瘤患者化疗前后细胞质胸苷激酶的变化及临床意义  

Change of TK1 Expression Level in NHL Patients before and after Chemotherapy and Its Clinical Significance

作　　者：吴宝花[1] 梁双吟[1] 郭熙哲[2] 

机构地区：[1]福建医科大学附属第二医院检验科,福建泉州362000 [2]福建医科大学附属第二医院血液内科,福建泉州362000

出　　处：《中国实验血液学杂志》2016年第5期1386-1389,共4页Journal of Experimental Hematology

摘　　要：目的:探讨非霍奇金淋巴瘤(NHL)患者化疗前后细胞质胸苷激酶(TK1)的变化及临床意义。方法:选取2013年7月-2016年1月期间我院收治的NHL患者108例作为研究对象,所有患者均接受化疗,比较完全缓解(CR)、部分缓解(PR)、疾病稳定(SD)及疾病进展(PD)患者治疗前后的TK1表达水平及其变化幅度。分析患者治疗后TK1水平与总生存期(OS)及无进展生存期(PFS)的相关性。结果:CR、PR及SD患者治疗后TK1水平明显下降(P<0.05)。CR患者治疗前TK1表达水平为1.49±0.34,治疗后为0.45±0.17,变化幅度为(68.12±5.41)%;PR患者治疗前和治疗后TK1表达水平分别是2.89±0.58,1.43±0.29及(50.27±4.82)%;PD患者治疗前和治疗后TK1表达水平分别是3.98±0.78,3.71±0.85和(5.04±0.31)%;SD患者治疗前和治疗后分别为3.49±0.92,2.45±0.57及(28.65±3.97)%,差异均具有统计学意义(P<0.05)。治疗后TK1水平与OS及PFS显著相关(r=0.457,P<0.05)。结论:非霍奇金淋巴瘤淋巴瘤患者TK1水平对患者的肿瘤负荷、治疗效果及预后具有提示意义。Objective：To study the change of TK1 expression level in patients with NHL and its clinical significance.Methods：A total of 108 NHL patients from July 2013 to January 2016 were chosen,all patients were treated with chemotherapy.The TK1 expression level and TK1 variation rate were compared among CR/PR/PD/DR patients.All patients were followed up,and the relation of TK1 level with OS/PFS was analyzed.Results：After treatment,the TK1 expression level of CR/PR/SD patients decreased significantly（P〈0.05）.Before treatment,the TK1 expression level of CR patients was 1.49 ±0.34,that after treatment was 0.45 ±0.17,the variation rate was（68.12±5.41）%;those of PR patients were respectively 2.89±0.58,1.43 ±0.29 and（50.27 ±4.82）%;those of PD patients were respectively 3.98±0.78,3.71±0.85 and（5.04±0.31）%;and those of SD patients were respectively3.49±0.92,2.45±0.57 and（28.65±3.97）%,the difference had statistic significance（P〈0.05）.After treatment,TK1 level related significantly with OS and PFS（P〈0.05）.Conclusion：TK1 expression level has suggested implications for the evaluation of tumor loading,and treatment effect as well as prognosis of patients with NHL.

关 键 词：非霍奇金淋巴瘤(NHL) 胸苷激酶1(TK1) 国际预后评分(IPI) 

分 类 号：R733.1[医药卫生—肿瘤]